<DOC>
	<DOCNO>NCT01012895</DOCNO>
	<brief_summary>The purpose study determine whether BMS-650032 BMS-790052 combination alone , together Ribavirin , together Interferon Ribavirin effective treatment Hepatitis C patient respond prior therapy .</brief_summary>
	<brief_title>Study Determine Effectiveness Antiviral Combination Therapy Treat Hepatitis C Virus ( HCV ) Infected Patients Who Have Previously Failed Standard Care</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Male female subject age 18 70 year HCVInfected Genotype 1 Null responder current standard care Expansion Cohorts A1 A2 restrict patient infected HCV Genotype 1b . Evidence medical condition associate chronic liver disease HCV History variceal bleeding , hepatic encephalopathy , ascites require management diuretic paracentesis History Cancer within 5 year enrollment History gastrointestinal disease surgical procedure ( except Cholecystectomy ) History clinically significant cardiac disease History Glucose6phosphate dehydrogenase ( G6PD ) deficiency Documented cirrhosis within 12 month prior dose Positive Human Immunodeficiency Virus ( HIV ) Hepatitis B Virus ( HBV ) Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>